A proof of concept study evaluating the potential benefit of Liquid Alpha-1 Antitrypsin (AAT) on liver preservation prior to transplantation.

Trial Profile

A proof of concept study evaluating the potential benefit of Liquid Alpha-1 Antitrypsin (AAT) on liver preservation prior to transplantation.

Planning
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Graft-versus-host disease; Liver transplant rejection
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 23 Feb 2017 New trial record
    • 21 Feb 2017 According to a Kamada media release, company has collaborated with Massachusetts General Hospital (MGH) to conduct this trial. This study will be led by James F. Markmann.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top